Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

PARIS, FRANCE, 25 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the first half of 2024. Business highlights U.S. regulatory approvals and launches of O

By: financialpost.com

Jul 25 2024
0
0 Views

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024

Quarterly Activities Report June 2024

A plan to replenish the Colorado River could mean dry alfalfa fields. And many farmers are for it

A neurological disorder stole her voice. Jennifer Wexton takes it back on the House floor.

Chinese Solar Group Urges Faster Consolidation as Glut Deepens

Publisher Jimmy Lai will testify in his defense at Hong Kong national security trial, lawyer says

ZoomerMedia Limited Announces Third Quarter 2024 Financial Results

LG Energy Slashes Sales Target After Earnings Miss Estimates

Russian Companies Face Mounting Payment Issues as Sanctions Bite

Oil Declines as China Concerns Eclipse Draw in US Stockpiles

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

Get Reliable Matka Guessing Forum with our Satta Matka Expert and Get all Matka Chart For Free.

Ipsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

Related